David Seaton

David has 30 years experience in the biopharmaceutical industry. From 1997 until 2011 he was Chief Financial Officer of Novogen Limited an ASX and NASDAQ listed biotech and Chief Financial Officer and Company Secretary of MEI Pharma (formally Marshall Edwards, Inc) a NASDAQ listed subsidiary of Novogen. He was Finance Director of GlaxoWellcome Australia from 1992 to 1997, and prior to that, Finance Director of Wellcome Australia where he also held a number of senior finance roles. David has a degree in Accountancy, a Masters Degree in Commerce and is a CPA.